Tee Meng Kian, Dong Qing, Miller Walter L
Department of Pediatrics and the Metabolic Research Unit, University of California, San Francisco, San Francisco, California 94143-0978, USA.
Endocrinology. 2008 May;149(5):2667-77. doi: 10.1210/en.2007-1527. Epub 2008 Jan 10.
Cytochrome P450c17 (P450c17) is the single enzyme that catalyzes steroid 17alpha-hydroxylase and 17,20 lyase activities and hence is the crucial decision-making step that determines the class of steroid made in a steroidogenic cell. Although both activities are catalyzed on a single active site, the ratio of these activities is regulated by posttranslational events. Serine phosphorylation of P450c17 increases 17,20 lyase activity by increasing the enzyme's affinity for its redox partner, P450 oxidoreductase. We searched for the relevant kinase(s) that phosphorylates P450c17 by microarray studies and by testing of kinase inhibitors. Microarrays show that 145 of the 278 known serine/threonine kinases are expressed in human adrenal NCI-H295A cells, only six of which were induced more than 2-fold by treatment with 8-Br-cAMP. Key components of the ERK1/2 and MAPK/ERK kinase (MEK)1/2 pathways, which have been implicated in the insulin resistance of PCOS, were not found in NCI-H295A cells, implying that these pathways do not participate in P450c17 phosphorylation. Treatment with various kinase inhibitors that probe the protein kinase A/phosphatidylinositol 3-kinase/Akt pathway and the calcium/calmodulin/MAPK kinase pathway had no effect on the ratio of 17,20 lyase activity to 17alpha-hydroxylase activity, appearing to eliminate these pathways as candidates leading to the phosphorylation of P450c17. Two inhibitors that target the Rho-associated, coiled-coil containing protein kinase (ROCK)/Rho pathway suppressed 17,20 lyase activity and P450c17 phosphorylation, both in NCI-H295A cells and in COS-1 cells transfected with a P450c17 expression vector. ROCK1 phosphorylated P450c17 in vitro, but that phosphorylation did not affect 17,20 lyase activity. We conclude that members of the ROCK/Rho pathway act upstream from the kinase that phosphorylates P450c17 in a fashion that augments 17,20 lyase activity, possibly acting to catalyze a priming phosphorylation.
细胞色素P450c17(P450c17)是唯一催化类固醇17α-羟化酶和17,20裂解酶活性的酶,因此是决定类固醇生成细胞中所产生类固醇类别的关键决策步骤。虽然这两种活性都在单一活性位点上催化,但这些活性的比例受翻译后事件的调节。P450c17的丝氨酸磷酸化通过增加该酶对其氧化还原伴侣细胞色素P450氧化还原酶的亲和力来提高17,20裂解酶活性。我们通过微阵列研究和激酶抑制剂测试寻找使P450c17磷酸化的相关激酶。微阵列显示,278种已知的丝氨酸/苏氨酸激酶中有145种在人肾上腺NCI-H295A细胞中表达,其中只有6种在用8-溴环磷酸腺苷处理后诱导增加超过2倍。与多囊卵巢综合征胰岛素抵抗有关的细胞外信号调节激酶1/2(ERK1/2)和丝裂原活化蛋白激酶/细胞外信号调节激酶激酶(MEK)1/2途径的关键成分在NCI-H295A细胞中未发现,这意味着这些途径不参与P450c17的磷酸化。用探测蛋白激酶A/磷脂酰肌醇3激酶/Akt途径和钙/钙调蛋白/丝裂原活化蛋白激酶激酶途径的各种激酶抑制剂处理对17,20裂解酶活性与17α-羟化酶活性的比例没有影响,似乎排除了这些途径作为导致P450c17磷酸化的候选途径。两种靶向Rho相关卷曲螺旋蛋白激酶(ROCK)/Rho途径的抑制剂在NCI-H295A细胞和用P450c17表达载体转染的COS-1细胞中均抑制了17,20裂解酶活性和P450c17磷酸化。ROCK1在体外使P450c17磷酸化,但该磷酸化不影响17,20裂解酶活性。我们得出结论,ROCK/Rho途径的成员在使P450c17磷酸化的激酶上游起作用,其方式是增强17,20裂解酶活性,可能起到催化引发磷酸化的作用。